AI powers Moderna's personalized cancer vaccine
Moderna and Merck just shared three-year follow-up data for their individualized cancer therapy mRNA-4157, showing sustained benefit in melanoma patients. Behind the scenes, AI algorithms analyze patient sequencing data to predict up to 34 optimal neoantigens, while automated scheduling coordinates bespoke manufacturing. Phase 3 trials are now underway.